Comments
Natco Pharma’s consolidated net profit declined 60 per cent at ₹120 crore in the fourth quarter ended March 31, 2019 as against ₹300 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based drug-maker also came down by 33 per cent at ₹487 crore (₹788 crore).
For the full year ended March 31, 2019, total revenue decreased marginally to ₹2,225 crore ( ₹2,242 crore). Net profit declined 7.6 per cent at ₹642 crore (₹695 crore).
The flu-season in the US was weaker than expected resulting in the write-off of this inventory valued at approximately $5.5 million, Natco said in a press release.
The board of directors has declared a third interim dividend of ₹1.25 per equity share of ₹2 each, resulting in a total dividend payout of ₹6.25 per equity share for the financial year 2018-19.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.